Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655064 in active lupus nephritis
NCT02770170Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2016
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of BI 655064 in lupus nephritis (LN), sponsored by Boehringer Ingelheim. Started May 2016; status: completed.
02
Drugs
BI 655064
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT02770170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770170.